Table 2 Cardiovascular outcomes.
Totala (n = 3924) | Normoglycemiab (n = 3141) | Diabetesc (n = 319) | |
|---|---|---|---|
CVD events including fatal | 362 | 283 | 60 |
Ischemic heart disease | 126 (34.8) | 96 (33.9) | 21 (35.0) |
Heart failure | 50 (13.8) | 37 (13.1) | 10 (16.7) |
Stroke | 127 (35.1) | 103 (36.4) | 18 (30.0) |
Vascular disease | 11 (3.0) | 10 (3.5) | 1 (1.7) |
Atrial fibrillation | 48 (13.3) | 37 (13.1) | 10 (16.7) |
CVD deaths | 111 (30.7) | 84 (29.7) | 20 (33.3) |